Trial reportChest2019
Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials.
Trial report in Chest, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05150483 (EndotyPIng PreHospitAl de Novo Acute hYpoxemic Respiratory Failure), which is not on this map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
EndotyPIng PreHospitAl de Novo Acute hYpoxemic Respiratory Failure
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Association between thrombocytopenia and development of acute respiratory distress syndrome.Respiratory research · 2026Pooled it
- Effect of Vitamin C on Clinical Outcomes of Critically Ill Patients With COVID-19: An Observational Study and Subsequent Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Pooled it
- Plasma matrix metalloproteinase-3 predicts mortality in acute respiratory distress syndrome: a biomarker analysis of a randomized controlled trial.Respiratory research · 2023Trial
- Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome.The New England journal of medicine · 2019Trial
- Is postoperative ARDS different from medical ARDS?Critical care (London, England) · 2026Article
- Successful Management of Severe COVID-19 in a Kidney Transplant Recipient Safe Co-Administered Tacrolimus and Ensitrelvir: A Case Report.Reports (MDPI) · 2026Article
- Improving retrospective ARDS case-finding using a simple 72-h physiologic persistence rule.Intensive care medicine experimental · 2026Article
- Beyond the PaOAnnals of intensive care · 2026Review
- Validation of PaO2:FiO2 for predicting hospital mortality in critically ill patients with acute hypoxaemic respiratory failure: a retrospective binational registry-based study.Critical care science · 2026Article
- Consensus statement for managing patients with ARDS in low-resource settings: a Delphi study.Annals of intensive care · 2026Article
- The utility of angiopoietin-2 and blood cell-derived biomarker indices in differentiating rapidly improving acute respiratory distress syndrome (RIARDS) phenotype from persistent-ARDS: a prospective observational study.Annals of medicine · 2025Observational
- Targeting PANoptosis: a promising therapeutic strategy for ALI/ARDS.Apoptosis : an international journal on programmed cell death · 2025Review
- Observational
- Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies.Signal transduction and targeted therapy · 2025Review
- Gravitational distribution of regional intrapulmonary shunt assessed by EIT in ARDS.Respiratory research · 2025Article
- Viral reactivations and fungal infections in nonresolving acute respiratory distress syndrome.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Clinical and biologic profiles of patients with acute respiratory distress syndrome by prevalence of chronic obstructive pulmonary disease or emphysema; a cohort study.Respiratory research · 2024Article
- Epidemiology of acute hypoxaemic respiratory failure in Australian and New Zealand intensive care units during 2005-2022. A binational, registry-based study.Intensive care medicine · 2024Article
- Incidence of acute kidney injury and attributive mortality in acute respiratory distress syndrome randomized trials.Intensive care medicine · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
backgroundObservational studies suggest that some patients meeting criteria for ARDS no longer fulfill the oxygenation criterion early in the course of their illness. This subphenotype of rapidly improving ARDS has not been well characterized. We attempted to assess the prevalence, characteristics, and outcomes of rapidly improving ARDS and to identify which variables are useful to predict it.
methodsA secondary analysis was performed of patient level data from six ARDS Network randomized controlled trials. We defined rapidly improving ARDS, contrasted with ARDS > 1 day, as extubation or a Pao
resultsThe prevalence of rapidly improving ARDS was 10.5% (458 of 4,361 patients) and increased over time. Of the 1,909 patients enrolled in the three most recently published trials, 197 (10.3%) were extubated on the first study day, and 265 (13.9%) in total had rapidly improving ARDS. Patients with rapidly improving ARDS had lower baseline severity of illness and lower 60-day mortality (10.2% vs 26.3%; P < .0001) than ARDS > 1 day. Pao
conclusionsRapidly improving ARDS, mostly defined by early extubation, is an increasingly prevalent and distinct subphenotype, associated with better outcomes than ARDS > 1 day. Enrollment of patients with rapidly improving ARDS may negatively affect the prognostic enrichment and contribute to the failure of therapeutic trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.